Prime Medicine PRME Research and development funding liability
Research and development funding liability at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept prme:ResearchAndDevelopmentFundingLiabilityNoncurrent.
The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Prime Medicine's research and development funding liability.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Prime Medicine's research and development funding liability?
- Prime Medicine (PRME) reported research and development funding liability of $18M in Q1 2026.
- How has Prime Medicine's research and development funding liability changed year-over-year?
- Prime Medicine's research and development funding liability increased by 50.0% year-over-year, from $12M to $18M.
- What does research and development funding liability mean?
- This metric represents long-term financial obligations arising from external research and development funding arrangements, such as grants, collaborative agreements, or non-dilutive financing structures. It reflects the company's future repayment obligations or performance-based commitments associated with the advancement of its proprietary gene editing pipeline. Tracking this liability is essential for assessing the company's long-term capital structure and the potential impact of future R&D-related cash outflows on liquidity.